- The shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) have received a $33 price target from Citi. These are the details.
The shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) have received a $33 price target from Citi. And Citi analyst Neena Bitritto-Garg increased the price target from $32 while maintaining a “Buy” rating on the shares.
Bitritto-Garg adjusted the rating while citing that the market opportunity for Albrioza in Canada alone is relatively small with an estimated $100 million in sales at the peak. And the approval bodes well for the ongoing U.S. and European reviews.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
